Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from […]
Read MoreWILMINGTON, N.C., Jan. 04, 2024 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, today announced its participation in the following investor conference: 26th Annual Needham Growth Conference Presentation: Wednesday, January 17, at 2:15 p.m. ET A live webcast, as well as a replay, will be available […]
Read MoreCompanies share commitment to innovating quality control processes to meet biomanufacturing challenges such as scale, data integrity and accelerating time to market LOWELL, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and […]
Read MoreCompany well-positioned for further progress and broadening of R&D pipeline Cash resources of approximately $455 million as of December 31, 2023 (unaudited) Expected cash runway, including proceeds from recent private placement, into 2H 2027 Top-line data readout from the Phase 3 trial evaluating zanidatamab in HER2-positive gastroesophageal adenocarcinoma (GEA), HERIZON-GEA-01, expected in 2024 Expected regulatory […]
Read MoreCompany well-positioned for further progress and broadening of R&D pipeline Cash resources of approximately $455 million as of December 31, 2023 (unaudited) Expected cash runway, including proceeds from recent private placement, into 2H 2027 Top-line data readout from the Phase 3 trial evaluating zanidatamab in HER2-positive gastroesophageal adenocarcinoma (GEA), HERIZON-GEA-01, expected in 2024 Expected regulatory […]
Read MoreDr. Jeffrey Smith named Executive Vice President and Chief Medical Officer Dr. John Fann promoted to Senior VP, Process Sciences Seven new Vice Presidents appointed, underscoring commitment to leadership development VANCOUVER, British Columbia, Jan. 04, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics […]
Read MoreMulilo Energy Holdings (Pty) (“Mulilo”), majority owned by Copenhagen Infrastructure Partners (“CIP”), has in partnership with EDF Renewables (Pty) Ltd (“EDF”) been awarded preferred bidder status for three battery energy storage projects totaling 1,028 MWh / 257 MW in South Africa COPENHAGEN, Denmark, Jan. 04, 2024 (GLOBE NEWSWIRE) — A consortium consisting of Mulilo, a […]
Read MoreHYDERABAD, INDIA – Media OutReach Newswire – 4 January 2024 – ACCESS Health International, a globally recognized health systems think tank and advisory group, today announced two important leadership transitions. Dr. N. Krishna Reddy, who has been leading the operations as President across Asia, Middle East, and North Africa, has been appointed Chief Executive Officer. Concurrently, the organization […]
Read More